CASPR
Center for Addiction Science, Policy, and Research

Center for Addiction Science, Policy, and Research

Our mission is to solve addiction at a population level.

CASPR pursues high-leverage strategies to advance novel medications for substance use disorders and to reduce rates of gambling addiction and bankruptcies.

Our pilot programs, the only two in the world providing GLP-1s to addiction patients, have received coverage in the New York Times, Washington Post, STAT, and many other publications.

CASPR PROGRAM NEWS

NIH High Leverage Trials (HILT) Proposal
February 2026

NIH High Leverage Trials (HILT) Proposal

A new policy brief proposing an NIH High-Leverage Trials program for large-scale drug repurposing and supplement research.

CASPR GLP-1 event with Congressional Addiction Caucus
January 2026

CASPR GLP-1 event with Congressional Addiction Caucus on Jan 13

If you are in DC, we'd love to have you join us.

Washington Post coverage
November 2025

Washington Post covers both of CASPR's GLP-1 pilot programs

Coverage of our programs at Caron and OpenDoors reaches DC policymakers.

NYT coverage
October 2025

New York Times covers our pilot program with Open Doors

GLP-1s for women in post-incarceration housing.

FDA Vouchers
August 2025

FDA's new National Priority Vouchers could grow the addiction medicine pipeline

A policy win that could accelerate drug approvals by 10 months.

Dr. Steve Klein
July 2025

STAT Coverage of Our Pilot Program at Caron Centers

Providing GLP-1s to inpatients with Dr. Steve Klein.

CASPR updates
April 2025

Updates on CASPR's Core Programs

Trials and projects that CASPR is running or making possible.

GLP-1s for Reducing Addiction
April 2025

GLP-1s for Reducing Addiction

Research and experiences from doctors and patients.

Chris Hayes podcast
January 2025

Podcast episode with Chris Hayes

Executive Director Nicholas Reville on addiction medicine, GLP-1s, and innovation policy.

An Innovation Agenda for Addiction
December 2024

An Innovation Agenda for Addiction

Federal policy proposals to accelerate breakthrough treatments for addiction, published with IFP and FAS.

VA study
November 2024

VA study on GLP-1s and opioid use in veterans

Our first collaboration with the Department of Veterans Affairs.

Addiction medicine doctors
September 2024

Addiction medicine doctors who use GLP-1s

"I'm now offering GLP-1s to nearly all my substance use disorder patients."

GRACE
July 2024

GRACE for Opioid Use Disorder

A novel GLP-1 based harm reduction strategy.